Expression of DNA topoisomerases in chronic proliferative kidney disease

Nassar, 1998, Novel approaches to treatment of glomerulonephritis, J Nephrol, 11, 177 Ambrus, 1997, Immunologic aspects of renal disease, JAMA, 278, 1938, 10.1001/jama.1997.03550220144019 Mohan, 1995, Lupus: Key pathogenic mechanisms and contributing factors, Clin Immunol Immunopathol, 77, 209, 10.1006/clin.1995.1146 Cameron, 1999, Lupus nephritis, J Am Soc Nephrol, 10, 413, 10.1681/ASN.V102413 Foster, 1999, Lupus nephritis: Update on pathogenesis and disease mechanisms, Semin Nephrol, 19, 173 Suzuki, 1997, Development of pathogenic anti-DNA antibodies in patients with systemic lupus erythematosus, FASEB J, 11, 1033, 10.1096/fasebj.11.12.9337156 Isenberg, 1997, The role of antibodies to DNA in systemic lupus erythematosus: A review and introduction to an international workshop on DNA antibodies held in London, May 1996, Lupus, 6, 290, 10.1177/096120339700600316 Suenaga, 1993, Cationic and high affinity serum IgG anti-dsDNA antibodies in active lupus nephritis, Clin Exp Immunol, 94, 418, 10.1111/j.1365-2249.1993.tb08211.x Kootstra, 1996, Characterization of reactivity of monoclonal autoantibodies with renal antigens in experimental lupus nephritis, J Clin Lab Immunol, 48, 201 Stojanov, 1995, Autoantibodies to topoisomerase I in a patient with systemic lupus erythematosus without features of scleroderma, Lupus, 4, 314, 10.1177/096120339500400414 Meliconi, 1989, Autoantibodies to DNA topoisomerase II in cryptogenic fibrosing alveolitis and connective tissue disease, Clin Exp Immunol, 76, 184 Hoffmann, 1989, Human autoantibody to topoisomerase II, Exp Cell Res, 180, 409, 10.1016/0014-4827(89)90067-0 Wang, 1985, DNA topoisomerases, Annu Rev Biochem, 54, 665, 10.1146/annurev.bi.54.070185.003313 Earnshaw, 1985, Topoisomerase II is a structural component of mitotic chromosome scaffolds, J Cell Biol, 100, 1706, 10.1083/jcb.100.5.1706 Suenaga, 1996, Anti-(DNA-histone) antibodies in active lupus nephritis, J Rheumatol, 23, 279 Wang, 1987, Recent studies of DNA topoisomerases, Biochim Biophys Acta, 909, 1, 10.1016/0167-4781(87)90040-6 Osheroff, 1989, Biochemical basis for the interactions of type I and type II topoisomerases with DNA, Pharmacol Ther, 41, 1, 10.1016/0163-7258(89)90108-3 D'arpa, 1995, Cell cycle-specific and transcription-related phosphorylation of mammalian topoisomerase I, Exp Cell Res, 217, 125, 10.1006/excr.1995.1071 Baker, 1995, Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy, Cytometry, 19, 134, 10.1002/cyto.990190208 Drake, 1989, Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II, Biochemistry, 28, 8154, 10.1021/bi00446a029 Woessner, 1991, Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells, Cell Growth Differ, 2, 209 Hwang, 1994, Cellular regulation of mammalian DNA topoisomerases, Adv Pharmacol, 29, 167, 10.1016/S1054-3589(08)60545-1 Negri, 1993, DNA topoisomerase II beta: Stability and distribution in different animal cells in comparison to DNA topoisomerase I and II alpha, Exp Cell Res, 206, 128, 10.1006/excr.1993.1128 Zini, 1992, The 180-kDa isoform of topoisomerase II is localized in the nucleolus and belongs to the structural elements of the nucleolar remnant, Exp Cell Res, 200, 460, 10.1016/0014-4827(92)90196-F Biersack, 1996, Active heterodimers are formed from human DNA topoisomerase II alpha and II beta isoforms, Proc Natl Acad Sci USA, 93, 8288, 10.1073/pnas.93.16.8288 Kellner, 1997, Detection of topoisomerase II alpha in cell lines and tissues: Characterization of five novel monoclonal antibodies, J Histochem Cytochem, 45, 251, 10.1177/002215549704500210 Mao, 1994, T cell receptor alpha-chain repertoire of pathogenic autoantibody-inducing T cells in lupus mice, J Immunol, 152, 1462, 10.4049/jimmunol.152.3.1462 Rajagopalan, 1992, Pathogenic autoantibody-inducing gamma/delta T helper cells from patients with lupus nephritis express unusual T cell receptors, Clin Immunol Immunopathol, 62, 344, 10.1016/0090-1229(92)90113-3 Zouali, 1994, Trigger mechanisms of autoantibody production, Clin Exp Rheumatol, 12, S33 Pawluczyk, 1997, Macrophages promote prosclerotic responses in cultured rat mesangial cells: A mechanism for the initiation of glomerulosclerosis, J Am Soc Nephrol, 8, 1525, 10.1681/ASN.V8101525 Wagrowska-Danilewicz, 1998, Intercellular adhesion molecule-1 (ICAM-1), leukocyte function-associated antigen-1 (LFA-1) and leukocyte infiltration in proliferative human glomerulonephritis, Acta Histochem, 100, 201, 10.1016/S0065-1281(98)80028-7 Hooke, 1987, Leukocyte analysis using monoclonal antibodies in human glomerulonephritis, Kidney Int, 31, 964, 10.1038/ki.1987.93 Hooke, 1984, Monoclonal antibody analysis of glomerular hypercellularity in human glomerulonephritis, Clin Nephrol, 22, 163 Ferrario, 1985, The detection of monocytes in human glomerulonephritis, Kidney Int, 28, 513, 10.1038/ki.1985.158 Wan, 1992, CDC14 of Saccharomyces cerevisiae: Cloning, sequence analysis, and transcription during the cell cycle, J Biol Chem, 267, 11274, 10.1016/S0021-9258(19)49907-9 Rudolph, 1997, Immunophenotyping of dermal spindle-cell tumors: Diagnostic value of monocyte marker Ki-M1p and histogenetic considerations, Am J Surg Pathol, 21, 791, 10.1097/00000478-199707000-00007 Oberholzer, 1983, Minimum sample size of kidney biopsies for semiquantitative and quantitative evaluation, Nephron, 34, 192, 10.1159/000183008 Bankfalvi, 1994, Moist autoclaving: A simplified method for antigen unmasking, Pathologe, 15, 345, 10.1007/s002920050064 Cordell, 1984, Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes), J Histochem Cytochem, 32, 219, 10.1177/32.2.6198355 Bohle, 1992, The long-term prognosis of the primary glomerulonephritides: A morphological and clinical analysis of 1747 cases, Pathol Res Pract, 188, 908, 10.1016/S0344-0338(11)80252-9 Rudolph, 1999, Prognostic significance of Ki-67 and topoisomerase II alpha expression in infiltrating ductal breast cancer: A multivariate analysis of 863 cases, Breast Cancer Res Treat, 55, 61, 10.1023/A:1006159016703 Rudolph, 1999, Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status, and proliferation in 356 node-negative ductal invasive carcinomas of the breast: Prognostic implications, J Pathol, 187, 207, 10.1002/(SICI)1096-9896(199901)187:2<207::AID-PATH223>3.0.CO;2-U Howie, 1995, Measurement of proliferation in renal biopsy specimens: Evidence of subclinical tubular damage in the nephrotic syndrome, Nephrol Dial Transplant, 10, 2212, 10.1093/ndt/10.12.2212 Abe, 1989, Significance of tubulointerstitial lesions in biopsy specimens of glomerulonephritic patients, Am J Nephrol, 9, 30, 10.1159/000167931 Husain, 1994, Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy, Cancer Res, 54, 539 Nangaku, 1998, Complement regulatory proteins in glomerular diseases, Kidney Int, 54, 1419, 10.1046/j.1523-1755.1998.00130.x Benigni, 1999, Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year, Kidney Int, 55, 674, 10.1046/j.1523-1755.1999.00288.x Ihm, 1998, A high glucose concentration stimulates the expression of monocyte chemotactic peptide 1 in human mesangial cells, Nephron, 79, 33, 10.1159/000044988 Wang, 1999, Induction of monocyte chemoattractant protein-1 by albumin is mediated by nuclear factor kappaB in proximal tubule cells, J Am Soc Nephrol, 10, 1204, 10.1681/ASN.V1061204 Beck-Schimmer, 1998, Hyaluronan induces monocyte chemoattractant protein-1 expression in renal tubular epithelial cells, J Am Soc Nephrol, 9, 2283, 10.1681/ASN.V9122283 Gerritsma, 1998, Transforming growth factor-beta 1 regulates chemokine and complement production by human proximal tubular epithelial cells, Kidney Int, 53, 609, 10.1046/j.1523-1755.1998.00799.x Duque, 1997, Interaction of IgA with Fc alpha receptors of human mesangial cells activates transcription factor nuclear factor-kappa B and induces expression and synthesis of monocyte chemoattractant protein-1, IL-8, and IFN-inducible protein 10, J Immunol, 159, 3474, 10.4049/jimmunol.159.7.3474 Pai, 1996, Role of tumor necrosis factor-alpha on mesangial cell MCP-1 expression and monocyte migration: Mechanisms mediated by signal transduction, J Am Soc Nephrol, 7, 914, 10.1681/ASN.V76914 Kovacs, 1994, Selective induction of PDGF gene expression in peritoneal macrophages by interleukin-2, Immunobiology, 190, 263, 10.1016/S0171-2985(11)80274-3 Allam, 1992, Differential expression of PDGF A- and B-chain genes and production of AA and AB dimers by activated human blood monocytes, Biochimie, 74, 1097, 10.1016/0300-9084(92)90008-3 Herrera-Esparza, 1998, Renal expression of IL-6 and TNFalpha genes in lupus nephritis, Lupus, 7, 154, 10.1191/096120398678919949 Ennulat, 1997, Mitogenic effects of epidermal growth factor and platelet-derived growth factor on canine and equine mesangial cells in vitro, Am J Vet Res, 58, 1308 Inoue, 1997, Lysophosphatidic acid and platelet-derived growth factor synergistically stimulate growth of cultured rat mesangial cells, Proc Soc Exp Biol Med, 216, 370, 10.3181/00379727-216-44184 Nabokov, 1997, Demonstration of the proliferation marker Ki-67 in renal biopsies: Correlation to clinical findings, Am J Kidney Dis, 30, 87, 10.1016/S0272-6386(97)90569-2 Groma, 1997, A quantitative immunohistochemical study of the expression of mesangial alpha-smooth muscle actin and the proliferation marker Ki-67 in glomerulonephritis in man, Virchows Arch, 431, 345, 10.1007/s004280050109 Yokoyama, 1992, Intraglomerular expression of MHC class II and Ki-67 antigens and serum gamma-interferon levels in IgA nephropathy, Nephron, 62, 169, 10.1159/000187028 Nakopoulou, 1997, The value of proliferating cell nuclear antigen (PCNA)/cyclin in the assessment of cell proliferation in glomerulonephritis, Histol Histopathol, 12, 655 Parwaresch, 1984, Origin and kinetics of resident tissue macrophages. Parabiosis studies with radiolabelled leukocytes, Cell Tissue Kinet, 17, 25 Radeke, 1993, Effects of cyclosporin and FK-506 on glomerular mesangial cells: Evidence for direct inhibition of thromboxane synthase by low cyclosporin concentrations, Eur J Clin Pharmacol, 44, S11, 10.1007/BF01428385 Hauser, 1999, Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion, Nephrol Dial Transplant, 14, 58, 10.1093/ndt/14.1.58 Siemann, 1999, Inhibition of cyclic AMP response element-binding protein/cyclic AMP response element-mediated transcription by the immunosuppressive drugs cyclosporin A and FK506 depends on the promoter context, Mol Pharmacol, 55, 1094, 10.1124/mol.55.6.1094 Rolfe, 1997, Cyclosporin A and FK506 reduce interleukin-5 mRNA abundance by inhibiting gene transcription, Am J Respir Cell Mol Biol, 17, 243, 10.1165/ajrcmb.17.2.2819 Thomson, 1995, Mode of action of tacrolimus (FK506): Molecular and cellular mechanisms, Ther Drug Monit, 17, 584, 10.1097/00007691-199512000-00007 Wiederrecht, 1993, The mechanism of action of FK-506 and cyclosporin A, Ann NY Acad Sci, 696, 9, 10.1111/j.1749-6632.1993.tb17137.x Hayashi, 1996, Suppression of experimental crescentic-type anti-glomerular basement membrane (GBM) nephritis by FK506 (tacrolimus hydrate) in rats, Jpn J Pharmacol, 70, 43, 10.1254/jjp.70.43 Ewesuedo, 1997, Topoisomerase I inhibitors, Oncologist, 2, 359, 10.1634/theoncologist.2-6-359 Cardenas, 1995, Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin, Curr Opin Nephrol Hypertens, 4, 472, 10.1097/00041552-199511000-00002 Andoh, 1998, Catalytic inhibitors of DNA topoisomerase II, Biochim Biophys Acta, 1400, 155, 10.1016/S0167-4781(98)00133-X Sehested, 1996, Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle, Biochem Pharmacol, 51, 879, 10.1016/0006-2952(95)02241-4